FCCP MD - Bright Minds Chief Officer
| DRUG Stock | USD 38.59 3.26 9.23% |
Insider
FCCP MD is Chief Officer of Bright Minds Biosciences
| Age | 61 |
| Address | 19 Vestry Street, New York, NY, United States, 10013 |
| Phone | 647 407 2515 |
| Web | https://brightmindsbio.com |
Bright Minds Management Efficiency
The company has return on total asset (ROA) of (0.2886) % which means that it has lost $0.2886 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.518) %, meaning that it created substantial loss on money invested by shareholders. Bright Minds' management efficiency ratios could be used to measure how well Bright Minds manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.29. The current Return On Capital Employed is estimated to decrease to -1.35. At this time, Bright Minds' Total Assets are most likely to increase significantly in the upcoming years. The Bright Minds' current Total Current Assets is estimated to increase to about 8.7 M, while Net Tangible Assets are projected to decrease to roughly 8.4 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Balu Balasubramanian | Pyxis Oncology | N/A | |
| Ben MD | Neurobo Pharmaceuticals | 68 | |
| Nandan BS | Immix Biopharma | 62 | |
| Chester III | Revelation Biosciences | 44 | |
| Martina BS | Pyxis Oncology | 59 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| David Hale | Dermata Therapeutics | 75 | |
| DSc MSE | Immix Biopharma | 75 | |
| Samuel MD | Altamira Therapeutics | 71 | |
| Jan Pinkas | Pyxis Oncology | N/A | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
| Gerald Proehl | Dermata Therapeutics | 65 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| JD MBA | Immix Biopharma | N/A | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| John CPA | Unicycive Therapeutics | 62 | |
| James Rolke | Revelation Biosciences | 55 | |
| David Dornan | Elevation Oncology | 46 | |
| Amro Albanna | Aditxt Inc | 54 | |
| MBA MD | Immix Biopharma | 49 | |
| Matthew Shatzkes | Aditxt Inc | N/A | |
Management Performance
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.29 |
Bright Minds Biosciences Leadership Team
Elected by the shareholders, the Bright Minds' board of directors comprises two types of representatives: Bright Minds inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Bright. The board's role is to monitor Bright Minds' management team and ensure that shareholders' interests are well served. Bright Minds' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Bright Minds' outside directors are responsible for providing unbiased perspectives on the board's policies.
| FCCP MD, Chief Officer | ||
| Alex Vasilkevich, COO Development | ||
| Jan MSc, Interim Director | ||
| Emer MBA, Consultant | ||
| Gideon Shapiro, VP Discovery | ||
| Ian McDonald, CEO, CoFounder |
Bright Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Bright Minds a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.29 | ||||
| Current Valuation | 242.02 M | ||||
| Shares Outstanding | 6.08 M | ||||
| Shares Owned By Insiders | 27.28 % | ||||
| Shares Owned By Institutions | 44.27 % | ||||
| Number Of Shares Shorted | 322.61 K | ||||
| Price To Book | 56.48 X | ||||
| EBITDA | (7.28 M) | ||||
| Net Income | (7.37 M) |
Currently Active Assets on Macroaxis
When determining whether Bright Minds Biosciences is a strong investment it is important to analyze Bright Minds' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Bright Minds' future performance. For an informed investment choice regarding Bright Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Bright Minds Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bright Minds. If investors know Bright will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bright Minds listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.29) | Return On Equity (0.52) |
The market value of Bright Minds Biosciences is measured differently than its book value, which is the value of Bright that is recorded on the company's balance sheet. Investors also form their own opinion of Bright Minds' value that differs from its market value or its book value, called intrinsic value, which is Bright Minds' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bright Minds' market value can be influenced by many factors that don't directly affect Bright Minds' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bright Minds' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bright Minds is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bright Minds' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.